Weight Gain And Comorbidities Associated With Oral Second-Generation Antipsychotics: Analysis Of Real-World Data For Patients With Bipolar I Disorder Or Schizophrenia

In this analysis of real-world data, both weight gain and treatment interruptions occurred early in treatment for patients with SZ or BD-I. Treatment-associated weight gain persisted despite switching or discontinuing index treatment. Additionally, cardiometabolic morbidity increased within 12 months of treatment initiation. Patients with SZ or BD-I are at greater risk than the general population for cardiometabolic conditions; weight gain associated with SGAs may exacerbate these health risks.